Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

The effects of incretin hormones on cerebral glucose metabolism in health and disease

Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Towards selective CNS PET imaging of the 5-HT7 receptor system: Past, present and future

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Reduced cortical serotonin 5-HT2A receptor binding and glutamate activity in high compulsive drinker rats

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Physiological roles of CNS muscarinic receptors gained from knockout mice

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Risk Factors for Being Seronegative following SARS-CoV-2 Infection in a Large Cohort of Health Care Workers in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Hemoglobin A1c-levels and subsequent risk of depression in individuals with and without diabetes

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Diabetic Neuropathy Influences Control of Spinal Mechanisms

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Gastrointestinal symptoms and cardiac vagal tone in type 1 diabetes correlates with gut transit times and motility index

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

Incretin hormones, notably glucagon-like peptide-1 (GLP-1), are gluco-regulatory hormones with pleiotropic effects also in the central nervous system. Apart from a local production of GLP-1, systemic administration of the hormone has been shown to influence a number of cerebral pathologies, including neuroinflammation. Given the brains massive dependence on glucose as its major fuel, we here review the mechanistics of cerebral glucose transport and metabolism, focusing on the deleterious effects of both hypo- and hyperglycaemia. GLP-1, when administered as long-acting analogues or intravenously, appears to decrease transport of glucose in normoglycaemic conditions, without affecting the total cerebral glucose content. During hypoglycaemia this effect seems abated, whereas during hyperglycaemia GLP-1 regulates cerebral glucose metabolism towards stable levels resembling normoglycaemia. In Alzheimer's disease, a 6-month intervention with GLP-1 maintained cerebral glucose levels at baseline levels, contrasting the decline otherwise seen in Alzheimer's. Kinetic studies suggest GLUT-1 as the key player in GLP-1 mediated effects on cerebral glucose metabolism.

OriginalsprogEngelsk
TidsskriftNeuropharmacology
Vol/bind136
Udgave nummerPart B
Sider (fra-til)243-250
Antal sider7
ISSN0028-3908
DOI
StatusUdgivet - jul. 2018

ID: 52331512